PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

NCT ID: NCT05052437

Last Updated: 2023-01-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-15
• Study Completion Date: 2021-02-19

Brief Summary

This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.

The purpose of this trial is:

1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone.

2. To evaluate the drug interaction of utidelone and capecitabine.

Conditions

Advanced and Metastatic Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Utidelone

Group Type: EXPERIMENTAL

Utidelone

Intervention Type: DRUG

8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.

Utidelone plus capecitabine

Group Type: EXPERIMENTAL

Utidelone Injection; capecitabine

Intervention Type: DRUG

8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle

Interventions

Utidelone Injection; capecitabine

8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle

Intervention Type: DRUG

Utidelone

8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign an informed consent form, have good compliance, and cooperate with relevant inspections.

2. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer.

3. Patients who have previously received at least one anthracycline and taxane drug therapy (neoadjuvant therapy, adjuvant therapy, or recurrence and metastasis therapy), or the investigator believes that they can be included in this study.

4. Age ≥18 years; physical condition score ECOG 0~2 points.

5. Within 4 weeks before enrollment, Neuropathy should be less than grade 2 (NCI CTCAE 5.0).

6. Within 1 week before enrollment, routine blood examinations were basically normal (based on the normal value of each research center laboratory):

1. White blood cell count (WBC) ≥3.0×109/L;

2. Neutrophil count (ANC) ≥ 1.5×109/L;

3. Platelet count (PLT) ≥100×109/L.

4. Hemoglobin ≥9g/dL.

7. Within 1 week before enrollment, liver and kidney function tests were basically normal (the normal value of each research center laboratory is standard):

1. Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN);

2. Alanine aminotransferase (SGPT/ALT)≤2.5×ULN (for liver metastases≤5×ULN);

3. Aspartate aminotransferase (SGOT/AST)≤2.5×ULN (for liver metastases≤5×ULN);

4. Creatinine clearance rate (Ccr) ≥60 ml/min.

8. No major organ dysfunction.

9. The patient must agree to provide blood, urine and stool samples for pharmacokinetic studies, and collect them in strict accordance with the required time points and intervals.

10. No mental abnormality, able to understand and undertake informed consent.

Exclusion Criteria

1. Those who need to receive non-investigative anti-cancer therapy (such as chemotherapy, immunotherapy or biological therapy) during the administration period of this trial.

2. People who are severely allergic to castor oil, or who have had serious adverse reactions to anti-microtubule drugs in the past.

3. Within 4 weeks before receiving treatment, have had any major surgery or suffered major trauma; or are expected to undergo major surgery during the treatment.

4. Pregnancy (positive pregnancy test), breastfeeding patients, or those who are unwilling to use contraception during the test;

5. Those with uncontrollable intracranial hypertension syndrome (persistent headache, short-term blurred vision, and/or diplopia)

6. Combined serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, severe infection, active peptic ulcer, etc.

7. Known HIV infection, or untreated active hepatitis B or C;

8. Known to have alcohol or drug addiction, or have a history of uncontrollable mental illness, lack of legal capacity or limited legal capacity;

9. The investigator believes that it is inappropriate to participate in this trial.

10. Participate in another clinical trial or use other research treatments at the same time.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Chengdu Biostar Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Quchang Ouyang, MD

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Locations

Hunan Cancer Hospital

Changsha, Hunan, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Countries

China

Other Identifiers

BG01-2001

Identifier Type: -

Identifier Source: org_study_id